{"entity":{"id":"nct04078295","kind":"trial","name":"A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor","aka":[],"tldr":"A phase 1/2 trial of Nivolumab in advanced solid tumours, run by Eisai Co., Ltd., active and no longer recruiting.","summary":"A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor is a phase 1/2 interventional study registered as NCT04078295 by Eisai Co., Ltd., with 125 participants enrolled, started 2019-09-05 and due to reach its primary completion in 2027-03-31. Interventions recorded: E7389-LF and Nivolumab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04078295","url":"https://clinicaltrials.gov/study/NCT04078295"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab"],"companies":["eisai","deciphera"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04078295","phase":"1/2","setting":"An Open-Label Phase 1b/2 Study of E7389 Liposomal Formulation Plus Nivolumab in Subjects With Solid Tumor","sponsor":"Eisai Co., Ltd.","enrolled":125,"outcomes":[]},"route":"/trials/nct04078295/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"deciphera","kind":"company","name":"Deciphera Pharmaceuticals (Ono)","route":"/companies/deciphera/"},{"id":"eisai","kind":"company","name":"Eisai","route":"/companies/eisai/"}]}}